Evidence map›Paper›PMID 42303760›Full record

ArticleNPJ precision oncology2026

Patient-derived three-dimensional lung tumor models to evaluate response to therapy.

Kayla F Goliwas, Aakash Desai, Kenneth P Hough, Sruti Sivan, Sierra L Single, Nithya Puritipati, Aroma G Tom, Sanad Alhushki, Sameer S Deshmukh, Joel L Berry and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Kayla F GoliwasDepartment of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. kfgoliwas@uabmc.edu.
Aakash DesaiDepartment of Medicine, Division of Hematology & Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Kenneth P HoughCytogence, Birmingham, AL, USA.
Sruti SivanDepartment of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Sierra L SingleDepartment of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Nithya PuritipatiDepartment of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Aroma G TomDepartment of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Sanad AlhushkiCytogence, Birmingham, AL, USA.
Sameer S DeshmukhCytogence, Birmingham, AL, USA.
Joel L BerryDepartment of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, USA.
Maya KhalilCytogence, Birmingham, AL, USA.
Benjamin WeiDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Yanis BoumberCytogence, Birmingham, AL, USA.
Mohammad AtharDepartment of Dermatology, University of Alabama at Birmingham, Birmingham, AL, USA.
Selvarangan PonnazhaganDepartment of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.
James M DonahueDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Jessy S DeshaneDepartment of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Omer Jamy · 1985 to 2026
$165.9M
Modeling Dynamic Immune Cell Modulation in a 3-D Tissue Engineered Platform to Enhance Patient-specific Immunotherapy for Lung CancerR21CA263365 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DESHANE, JESSY SATYADAS · 2022 to 2023
$378k
NCI NIH HHS P30 CA013148NCI NIH HHS R21 CA263365
6 · The paper itself

Abstract

Novel preclinical models that better mimic the in vivo tumor microenvironment are essential to advance understanding of tumor biology and resistance/response to therapy. Herein, we report development of a novel ex vivo patient-derived three-dimensional lung tumor model (3D-LTM) for use in evaluating response to therapy. With this model system that maintains cell-cell interactions and tissue architecture, we observed heterogeneity of response to immune checkpoint inhibitors (ICI), as noted in non-small cell lung cancer (NSCLC) patients, and defined gene signatures associated with response. Spatial transcriptomics identified positive correlation of CD8

Identifiers

PMID42303760
PMCPMC13631226

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.